Literature DB >> 12853696

Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab.

Wenche Jy1, Teresa Gagliano-DeCesare, Daniel H Kett, Lawrence L Horstman, Joaquin J Jimenez, Zoneddy Ruiz-Dayao, Edgardop S Santos, Yeon S Ahn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853696     DOI: 10.1159/000070973

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  5 in total

Review 1.  Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review.

Authors:  Koji Yamamoto; Junki Takamatsu; Hidehiko Saito
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

Review 2.  Rituximab for eradicating inhibitors in people with acquired haemophilia A.

Authors:  Tracey Remmington; Sherie Smith
Journal:  Cochrane Database Syst Rev       Date:  2021-08-23

Review 3.  Acquired hemophilia: a rare but life-threatening potential cause of bleeding in the intensive care unit.

Authors:  Aryeh Shander; Christopher E Walsh; Caroline Cromwell
Journal:  Intensive Care Med       Date:  2011-05-31       Impact factor: 41.787

4.  Acquired hemophilia as the cause of life-threatening hemorrhage in a 94-year-old man: a case report.

Authors:  Theodoros Kelesidis; Jonelle Raphael; Elizabeth Blanchard; Rekha Parameswaran
Journal:  J Med Case Rep       Date:  2010-07-29

Review 5.  The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A.

Authors:  Giovanni D'arena; Elvira Grandone; Matteo N D Di Minno; Pellegrino Musto; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2015-09-03       Impact factor: 3.443

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.